| Literature DB >> 21991302 |
Melissa A Bourgeois1, Nancy D Denslow, Kathy S Seino, David S Barber, Maureen T Long.
Abstract
Gene expression associated with West Nile virus (WNV) infection was profiled in the central nervous system of horses. Pyrosequencing and library annotation was performed on pooled RNA from the CNS and lymphoid tissues on horses experimentally infected with WNV (vaccinated and naïve) and non-exposed controls. These sequences were used to create a custom microarray enriched for neurological and immunological sequences to quantitate gene expression in the thalamus and cerebrum of three experimentally infected groups of horses (naïve/WNV exposed, vaccinated/WNV exposed, and normal).From the sequenced transcriptome, 41,040 sequences were identified by alignment against five databases. 31,357 good sequence hits (e<10(-4)) were obtained with 3.1% of the sequences novel to the equine genome project. Sequences were compared to human expressed sequence tag database, with 31,473 equine sequences aligning to human sequences (69.27% contigs, 78.13% seed contigs, 80.17% singlets). This indicated a high degree of sequence homology between human and equine transcriptome (average identity 90.17%).Significant differences (p<0.05) in gene expression were seen due to virus exposure (9,020), survival (7,395), and location (7,649). Pathways analysis revealed many genes that mapped to neurological and immunological categories. Involvement of both innate and adaptive components of immunity was seen, with higher levels of expression correlating with survival. This was highlighted by increased expression of suppressor of cytokine signaling 3 in horses exposed to WNV which functions to suppress innate immunity. Pentraxin 3 was most increased in expression for all horses exposed to WNV.Neurological pathways that demonstrated the greatest changes in gene expression included neurotransmitter and signaling pathways. Decreased expression of transcripts in both the glutamate and dopamine signaling pathways was seen in horses exposed to WNV, providing evidence of possible glutamate excitotoxicity and clinical signs associated with decreased dopamine. Many transcripts mapped to non-infectious neurological disease functions, including mental disorders and degenerative neuropathies.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21991302 PMCID: PMC3186766 DOI: 10.1371/journal.pone.0024371
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Samples and analyses for the array.
| Analysis | Samples | Tissue type | WNV Challenge |
| Exposure Status | Not vaccinated- 6 horses | Thalamus | Y |
| Untreated- 6 horses | Thalamus | N | |
| Survival/Immune Status | Not vaccinated- 6 horses | Thalamus | Y |
| Vaccinated- 6 horses | Thalamus | Y | |
| CNS Location | Not vaccinated- 6 horses | Thalamus | Y |
| Not vaccinated- 6 horses | Cerebrum | Y |
A total of 12 tissues were compared for each of the analyses/questions asked. The questions included determining if there was a difference in gene expression due to exposure to WNV, recovery from WNV infection, and location in the brain.
Data from 454 Sequencing Runs Paracel Transcript Assembler.
| Classification | Number of Sequences |
| No. of current input sequences | 483,227 |
| No. of sequences removed during cleanup | 294,342 (609 were EquCabv2 genes) |
| No. of sequences kept after cleanup | 188,885 (22,139 were EquCabv2 genes) |
| No. of sequences in seed clusters | 61,499 |
| No. of sequences pairwise compared | 127,386 |
| No. of singlets after pairwise compared | 75,413 |
| No. of problem sequences | 54 |
| No. sequences in clusters | 51,919 |
| No. of seed clusters | 21,421 |
| No. of clusters | 11,634 |
| Largest cluster | cl.007 (2,998) |
| 2nd largest cluster | cl.015 (2,721) |
| Largest seed cluster | sd.17584 (112) |
| 2nd largest seed cluster | sd.3613 (105) |
| No. final assemblies | 134,844 |
| No. of cluster.contigs | 11,621 |
| No. of cluster singlets | 2,098 (4 genes+19 newbler contig+2,075 reads) |
| No. of seed cluster.contigs | 8,058 |
| No. of seed cluster singlets | 37,654 (*21,021 genes+29 newbler contig+2,498 reads) |
| No. of PTA contigs | 19,679 (11,621+8,058) |
| No. of singlet | 75,413 (28 genes+260 newbler contig+75,125 reads) |
| No. of contigs | 19,987 ( = 11,621+8,058+19+29+260) |
| No. of genes | 21,053 ( = 4+21,021+28) |
Summary of BLAST Results for Five Separate Databases.
| Count | % | NR/NT | Equ-Cab2 Chr. | Equ-Cab2 Predicted Genes | Equ-Cab2 GeneScan | Newbler Contigs | Cluster Contigs | Seeded Cluster Contigs | Equ-Cab2 Genes |
| 28,789 | 70.1 | √ | √ | √ | 58 | 412 | 7,760 | 20,559 | |
| 817 | 2.0 | √ | √ | × | 37 | 360 | 219 | 201 | |
| 652 | 1.6 | √ | × | √ | 11 | 641 | 0 | 0 | |
| 5,391 | 13.1 | e-value | √ | × | × | 65 | 5,326 | 0 | 0 |
| 2,462 | 6.0 | e-value | √ | × | × | 61 | 2,401 | 0 | 0 |
| 1,651 | 4.0 | √ | × | × | 50 | 1,601 | 0 | 0 | |
| 677 | 1.6 | e-value | × | × | × | 13 | 299 | 79 | 286 |
| 287 | 0.7 | e-value | × | × | × | 9 | 273 | 0 | 5 |
| 314 | 0.8 | × | × | × | 4 | 308 | 0 | 2 | |
| 41,040 | 308 | 11,621 | 8,058 | 21,053 |
= e-value<1e−20,
= e-value<1e−4.
Summary of BLAST Analysis of Sequenced Equine Transcriptome to the Human Expressed Sequence Tag Database.
| Contigs | Seed Contigs | Singlets | |
| Number of Matches E≤10−4 | 8050/11621 | 6296/8058 | 17127/21361 |
| Percent Homology Match | 69.27% | 78.13% | 80.17% |
| Average E value | 1.44636E-05 | 2.38671E-06 | 8.09623E-06 |
| Average Bit Score | 189.0196894 | 907.9956004 | 519.9152099 |
| % Identity | 89% | 91% | 90% |
| Alignment Length | 187.9218634 | 698.33831 | 435.6858761 |
Contigs, seed contigs, and singlets from this project were BLASTed against the human EST database. In total, 31,473 sequences matched to the human EST database (row 1) with an e-value≤10−4.
Figure 1Neurological canonical pathways for all analyses.
Canonical pathways identified as significant for each analysis were selected. There was a high degree of overlap between all three analyses in neurological pathways. The location analysis contained transcripts that mapped to the most neurological pathways. The green line represents significance. For the purposes of this study, ‘exposure’ represents the difference in gene expression between the nonvaccinated/exposed-normal, ‘survival’ represents the difference in gene expression between the nonvaccinated/exposed-vaccinated/exposed, and ‘location’ represents the difference in gene expression between the thalamus and cerebrum of the nonvaccinated/exposed.
Figure 2Glutamate and Dopamine Receptor Signaling Pathways.
(A) The diagrams represents signaling in the synaptic cleft (square = pre-synaptic neuron, oval = post-synaptic neuron, circle = glial cell). Green represents downregulation of pertinent receptors, red represents upregulation of pertinent receptors. WNV induces downregulation of glutamate receptors on the post-synaptic cleft as well as glutamate uptake receptors on glial cells. (B) Dopamine receptor signaling pathway. The graphic shown is for the exposure analysis, but was similar in all analyses. Green represents down-regulation of transcripts, red represents upregulation. Dopamine receptors (DRD5) and downstream signaling pathways as well as enzymes that create dopamine (TH) were downregulated, while MAO (enzyme that degrades dopamine) was upregulated. This network was generated through the use of IPA (Ingenuity Systems, www.ingenuity.com).
Levels of Expression of Transcripts in Neurological Pathways of Note.
| Entrez Gene Name | GenBank | Exposure | Exposure (p-value) | Survival | Survival p-value | Location | Location p-value |
| Adenylate cyclase 1 (brain) | NM_174229 | −1.789 | 1.78E-02 | −1.898 | 1.25E-02 | ||
| Adenylate cyclase 2 (brain) | XM_851103 | −1.683 | −8.70E-08 | −1.223 | 4.90E-06 | −2.027 | 6.80E-09 |
| Adenylate cyclase 5 | NM_183357 | −1.258 | 2.07E-02 | −1.379 | 1.19E-02 | ||
| Adenylate cyclase 8 (brain) | XM_539166 | −1.021 | 2.11E-02 | −1.954 | 4.50E-05 | ||
| Adenylate cyclase 9 | BC151229 | −1.46 | 5.00E-04 | ||||
| Calcium/calmodulin-dependent protein kinase IV | XM_517873 | −1.976 | 6.20E-03 | ||||
| Dopamine receptor D5 | XM_604584 | −1.097 | 1.72E-02 | ||||
| GTP cyclohydrolase 1 | XM_846790 | 1.296 | 3.00E-03 | ||||
| Glutaminase | AC005540 | −1.009 | 9.00E-04 | ||||
| Guanine nucleotide binding protein (G protein), beta polypeptide 1 | BC004186 | −1.638 | 7.80E-03 | ||||
| Guanine nucleotide binding protein (G protein), gamma 5 | BC003563 | 1.359 | 4.40E-05 | ||||
| Glutamate receptor, ionotropic, AMPA 1 | XM_001169416 | −1.398 | 1.34E-02 | −1.057 | 5.00E-04 | −1.498 | 3.00E-04 |
| Glutamate receptor, ionotropic, AMPA 2 | NM_000826 | −1.505 | 4.00E-03 | −1.643 | 3.90E-05 | ||
| Glutamate receptor, ionotrophic, AMPA 3 | NM_007325 | −2.33 | 2.50E-03 | −2.719 | 3.00E-04 | ||
| Glutamate receptor, ionotrophic, AMPA 4 | NM_000829 | 1.253 | 1.50E-02 | −1.039 | 3.10E-03 | ||
| Glutamate receptor, ionotropic, delta 2 | AC022317 | −1.581 | 1.00E-04 | ||||
| Glutamate receptor, ionotropic, kainate 1 | NM_000830 | −1.098 | 2.59E-02 | −1.933 | 1.57E-02 | −2.626 | 3.00E-04 |
| Glutamate receptor, ionotropic, kainate 2 | XM_866973 | −1.533 | 1.57E-02 | ||||
| Glutamate receptor, ionotropic, N-methyl D-aspartate 1 | AF015731 | −1.949 | 6.00E-03 | −1.487 | 1.99E-02 | ||
| Glutamate receptor, ionotropic, N-methyl D-aspartate 2A | XM_547132 | −2.836 | 1.00E-04 | −1.631 | 2.85E-02 | −2.369 | 1.00E-03 |
| Glutamate receptor, ionotropic, N-methyl D-aspartate 2B | AC007535 | −1.563 | 7.40E-03 | −1.989 | 2.05E-02 | ||
| Glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | XM_862276 | −1.032 | 1.10E-03 | ||||
| Glutamate receptor interacting protein 1 | XM_001162097 | −1.23 | 2.83E-02 | ||||
| Glutamate receptor, metabotropic 8 | AC079957 | −1.856 | 1.14E-02 | ||||
| Homer homolog 1 (Drosophila) | XM_001139767 | −1.084 | 2.81E-02 | ||||
| Homer homolog 3 (Drosophila) | XM_541929 | −1.718 | 1.10E-03 | −1.134 | 2.31E-02 | ||
| Interleukin 4 induced 1 | AY358933 | 3.176 | 3.00E-05 | 3.265 | 2.00E-05 | 1.405 | 3.79E-02 |
| Protein phosphatase 1, regulatory (inhibitor) subunit 14A | XM_867134 | −2.083 | 1.10E-03 | ||||
| Protein phosphatase 1, regulatory (inhibitor) subunit 3C | BT030698 | −2.27 | 9.00E-04 | −1.746 | 7.00E-12 | −1.686 | 2.00E-11 |
| Protein phosphatase 2 (formerly 2A), regulatory subunit B, beta isoform | XM_001159292 | −2.348 | 1.00E-04 | 1.14 | 3.49E-02 | ||
| Protein phosphatase 2 (formerly 2A), regulatory subunit B, gamma isoform | XM_001250700 | −1.243 | 2.80E-03 | −1.378 | 1.10E-03 | −1.446 | 7.00E-04 |
| Protein kinase, camp-dependent, catalytic, beta | XM_862471 | −2.225 | 7.00E-04 | ||||
| Protein kinase, camp-dependent, regulatory, type II, beta | XM_001148361 | −1.627 | 2.20E-03 | ||||
| Solute carrier family 1 (glial high affinity glutamate transporter), member 2 | NM_004171 | −1.639 | 1.53E-02 | −2.869 | 7.80E-06 | −2.278 | 2.00E-04 |
| Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 | NM_001098046 | −1.598 | 8.23E-02 | −2.652 | 4.20E-03 | −8.147 | 9.50E-08 |
| Tyrosine hydroxylase | BC149072 | −2.857 | 1.00E-03 |
-Involved with Dopamine Signaling Pathway,
- Involved with Glutamate Signaling Pathway.
Figure 3Immunological Canonical Pathways for All Analyses.
The location analysis contained transcripts that mapped to the most immunological pathways. The green line indicates significance. For the purposes of this study, ‘exposure’ represents the difference in gene expression between the nonvaccinated/exposed-normal, ‘survival’ represents the difference in gene expression between the nonvaccinated/exposed-vaccinated/exposed, and ‘location’ represents the difference in gene expression between the thalamus and cerebrum of the nonvaccinated/exposed.
Figure 4IL-15 Production Pathway and IL-22 Signaling Pathway.
(A) The diagrams represent the different methods of IL-15 production. Green represents downregulation of pertinent molecules, red represents upregulation of pertinent molecules. WNV induces upregulation of the production of IL-15. (B) Red represents upregulation of gene expression, green represents down-regulation of gene expression. The JAK/STAT portion of the pathway is upregulated during viral infection, demonstrating an innate immune response. However, the SOCS3 molecule is also upregulated, indicating that infection with the virus may lead to subsequent suppression of the JAK/STAT pathway and evasion of the innate immune response. This network was generated through the use of IPA (Ingenuity Systems, www.ingenuity.com).
Levels of Expression of Transcripts in Immunological Pathways of Note.
| Entrez Gene Name | GenBank | Exposure | Exposure p-value | Survival | Survival p-value | Location | Location p-value |
| Interleukin 15 | AK290619 | 2.369 | 7.40E-06 | 2.29 | 1.20E-05 | 2.004 | 4.00E-03 |
| Interferon regulatory factor 3 | AK292027 | 1.31 | 1.80E-03 | 1.935 | 2.00E-05 | 1.086 | 3.32E-04 |
| Janus kinase 1 | XM_001161295 | 1.079 | 1.10E-03 | ||||
| Mitogen-activated protein kinase kinase 1 | XM_612526 | −1.4 | 3.79E-02 | ||||
| Mitogen-activated protein kinase 1 | NM_002745 | −1.095 | 6.40E-03 | −1.061 | 9.50E-03 | ||
| Protein inhibitor of activated STAT, 2 | XM_612798 | −1.014 | 1.20E-02 | ||||
| Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | NM_181504 | −1.062 | 3.00E-04 | −1.339 | 1.00E-04 | ||
| Phosphoinositide-3-kinase, regulatory subunit 2 (beta) | XM_847313 | −2.44 | 2.40E-03 | −2.341 | 1.15E-02 | ||
| Phosphoinositide-3-kinase, regulatory subunit 3 (gamma) | XM_856294 | 1.537 | 2.43E-02 | ||||
| PTK2B protein tyrosine kinase 2 beta | XM_543228 | −1.029 | 8.60E-03 | −1.545 | 1.10E-03 | ||
| Suppressor of cytokine signaling 3 | NM_174466 | 1.535 | 1.45E-02 | 1.809 | 4.60E-03 | ||
| Signal transducer and activator of transcription 1, 91kda | BC151378 | 3.021 | 3.00E-18 | 3.763 | 5.00E-20 | 2.384 | 1.00E-14 |
| Tyrosine kinase 2 | XM_590006 | 1.504 | 2.00E-04 |
- Involved with IL-15 Signaling Pathway,
- Involved with IL-9;IL-22;JAK/STAT Signaling Pathways.
Figure 5Neurological Functions for All Analyses.
(A) Neurological disease and psychological disorders categories, and (B) Nervous system development and function and behavior categories. The majority of transcripts mapped to neurological disease. The red bars represent the exposure analysis, the purple bars the survival analysis, and the orange bars the location analysis. The diamonds represent the p-value for exposure, the triangles the p-value for nonsurvival, and the squares the p-value for location. For the purposes of this study, ‘exposure’ represents the difference in gene expression between the nonvaccinated/exposed-normal, ‘survival’ represents the difference in gene expression between the nonvaccinated/exposed-vaccinated/exposed, and ‘location’ represents the difference in gene expression between the thalamus and cerebrum of the nonvaccinated/exposed.
Transcripts for all analyses mapped to neurological CPs.
| Exposure Decreased | Exposure Increased | Survival Decreased | Survival Increased | CNS Location Decreased | CNS Location Increased | |
| Agrin Interactions at Neuromuscular Junction | 1 | 4 | 2 | 2 | 2 | 4 |
| Amyloid Processing | 4 | 1 | 3 | 1 | 3 | 3 |
| Amyotrophic Lateral Sclerosis Signaling | 11 | 1 | 14 | 0 | 13 | 2 |
| Axonal Guidance Signaling | 25 | 6 | 22 | 7 | 19 | 10 |
| CDK5 Signaling | 11 | 0 | 9 | 0 | 10 | 2 |
| Cholecystokinin/Gastrin-mediated Signaling | 5 | 2 | 7 | 2 | 6 | 1 |
| Circadian Rhythm Signaling | 2 | 1 | 4 | 1 | 5 | 1 |
| CNTF Signaling | 1 | 2 | 2 | 1 | 4 | 3 |
| CREB Signaling in Neurons | 15 | 4 | 19 | 2 | 20 | 4 |
| Docosahexaenoic Acid (DHA) Signaling | 2 | 0 | 2 | 1 | ||
| Dopamine Receptor Signaling | 10 | 1 | 6 | 2 | 6 | 2 |
| GABA Receptor Signaling | 6 | 0 | 6 | 0 | 8 | 0 |
| Glutamate Receptor Signaling | 8 | 1 | 15 | 0 | 12 | 1 |
| GNRH Signaling | 12 | 3 | 11 | 1 | 13 | 2 |
| Huntington's Disease Signaling | 10 | 5 | 8 | 5 | 12 | 7 |
| Melatonin Signaling | 6 | 1 | 10 | 1 | 8 | 1 |
| Neuregulin Signaling | 6 | 3 | 10 | 6 | ||
| Neuropathic Pain Signaling In Dorsal Horn Neurons | 8 | 2 | 16 | 1 | 17 | 2 |
| Neurotrophin/TRK Signaling | 5 | 0 | 4 | 0 | 6 | 2 |
| Reelin Signaling in Neurons | 4 | 2 | 3 | 3 | 5 | 5 |
| Regulation of Actin-based Motility by Rho | 3 | 2 | ||||
| Semaphorin Signaling in Neurons | 6 | 1 | 5 | 2 | 2 | 1 |
| Serotonin Receptor Signaling | 1 | 1 | 0 | 2 | 1 | 1 |
| Synaptic Long Term Depression | 14 | 4 | 17 | 3 | 17 | 3 |
| Synaptic Long Term Potentiation | 11 | 1 | 15 | 1 | 17 | 1 |
| Total | 176 | 43 | 209 | 42 | 218 | 65 |
This table shows the number of transcripts that mapped to each pathway for all analyses. The majority of the transcripts demonstrated a decrease in expression values. Transcripts were included if they demonstrated a fold change >1 or <−1.
Summary of outcomes of each treatment group analyzed by CNS microarray.
| Vaccine | Clinical Signs | Fever | Survival | Virus Isolation | Histopathology |
|
| 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
|
| 6/6 | 3/6 | 6/6 | 6/6 | 6/6 |
|
| 0/0 | 0/0 | 0/0 | 0/0 | 0/0 |
Moderate or severe signs in at least one of the following categories for at least two days: mentation, paresis, fasciculation, or ataxia.
Body temperature ≥39.2°C (102.5°F).
Death due to development of WNV disease severe enough to require euthanasia for humane reasons.
Encephalitic horses in the control group had moderate or severe encephalitis on histopathology.
Mild inflammatory histopathologic changes in neural tissues vaccinated horses.
Histopathology on individual animals.
| Treatment | Animal | Pathology Score in Cerebrum | Pathology Score in Thalamus |
|
|
| 0(18) | 0(17) |
|
|
| 1(13) | 1(12) |
|
|
| 0(10) | 3(43) |
|
|
| 0(2) | 1(17) |
|
|
| 0(7) | 0(3) |
|
|
| 0(2) | 0(10) |
|
|
| 2(40) | 29(93) |
|
|
| 4(58) | 18(100) |
|
|
| 6(60) | 11(82) |
|
|
| 7(75) | 17(83) |
|
|
| 0 (8) | 10(32) |
|
|
| 1(10) | 7(50) |
|
|
| 0 | 0 |
|
|
| 0 | 0 |
|
|
| 0 | 0 |
|
|
| 0 | 0 |
|
|
| 0 | 0 |
|
|
| 0 | 0 |
This table shows the lesions that were quantified in the pons, medulla, cervical cord and lumbar cord. Briefly cross sections of these areas were examined for the presence of gliosis and perivascular cuffing. One section each was evaluated for the pons and medulla. Two sections were evaluated for each area of the spinal cord. Total numbers of glial nodules were counted in each section. If more than one section was evaluated the counts for these sections were averaged. For pervascular cuffs, 3 areas were examined in each section and 10 vessels were counted in each area. The number of vessels that contained inflammatory cells was divided by the number 10. Each area per section was averaged.
Validation of the array.
| Nonvaccinate average relative expression QPCR | Vaccinate average relative expression QPCR | Average expression nonvaccinate: vaccinate QPCR | Nonvaccinate: vaccinate array expression | |
| 2′5′OAS | +1.689667 | −0.71533 | +2.4050 | +6.539663 |
| Complement Component 1 r | +2.0895 | −0.2185 | +2.3080 | +1.886843 |
| DEADBox60 | +1.7625 | −0.895 | +2.6575 | +5.651655 |
| Defensin B4 | +0.365333 | −1.907 | +2.2723 | +6.99401 |
| IL-6 | +1.342833 | −0.56933 | +1.9122 | +5.97945 |
| TNF | +0.649 | −0.90583 | +1.5548 | +3.471118 |
Comparison of the relative expression levels between the nonvaccinate and vaccinate thalamus and QPCR to array platforms.